title: The burden of osteoporosis in Brazil.
abstract: Osteoporotic fractures impose severe physical, psychosocial, and financial burden both to the patient and the society. Studies on the prevalence of osteoporosis and fragility fractures in Brazil show a wide variation, due to differences in sample size, the population studied, and methodologies. Few studies have been conducted in Brazil about the cost-effectiveness analyses of different intervention options aimed at the diagnosis and treatment of osteoporosis. Investigation and treatment strategies based on cost-effectiveness and scientific evidence are essential in the preparation of public health policies with the ultimate goal of reducing the incidence of fractures and, consequently, the direct and indirect costs associated with them. This article reviews the Brazilian burden of osteoporosis in terms of the prevalence and fractures attributable to the disease, the costs related to the investigation and management, as well as the impact of osteoporosis on the population as a whole and on affected individuals.
authors.affiliation: Hospital Felício Rocho, Belo Horizonte, MG, Brazil.
authors.forename: Bruna Coelho Galvão
authors.initials: BC
authors.lastname: Marinho
authors.affiliation: Hospital Felício Rocho, Belo Horizonte, MG, Brazil.
authors.forename: Luiza Paulino
authors.initials: LP
authors.lastname: Guerra
authors.affiliation: Laboratório Hermes Pardini, Belo Horizonte, MG, Brazil.
authors.forename: Juliana Beaudette
authors.initials: JB
authors.lastname: Drummond
authors.affiliation: INCT, Medicina Molecular, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
authors.forename: Barbara C
authors.initials: BC
authors.lastname: Silva
authors.affiliation: Faculdade de Medicina, UFMG, Belo Horizonte, MG, Brazil.
authors.forename: Maria Marta Sarquis
authors.initials: MM
authors.lastname: Soares
mesh_terms: D015502:Absorptiometry, Photon; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001938:Brazil / Q000453:epidemiology; D002136:Calcium, Dietary / Q000627:therapeutic use; D017281:Cost of Illness; D003362:Cost-Benefit Analysis / Q000191:economics; D016206:Databases, Bibliographic; D006291:Health Policy / Q000191:economics; D006801:Humans; D015994:Incidence; D010024:Osteoporosis / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D015663:Osteoporosis, Postmenopausal / Q000191:economics; D058866:Osteoporotic Fractures / Q000191:economics / Q000453:epidemiology; D015995:Prevalence; D011788:Quality of Life; D014807:Vitamin D / Q000627:therapeutic use
chemical_list: D050071:Bone Density Conservation Agents; D002136:Calcium, Dietary; D014807:Vitamin D